Articles related to STEM CELLS

In a recent study, 91% of patients with transfusion-dependent β-thalassemia achieved independence from transfusions following treatment with Exagamglogene Autotemcel.

Primary care physicians are crucial in managing the intricate health complications of allogeneic HCT survivors, including chronic graft-vs-host disease and increased cardiovascular risks.

In a recent study involving patients with CD7-positive leukemia and lymphoma, an integrated approach of CAR T-cell therapy followed by haploidentical HSCT resulted in a one-year disease-free survival rate of 54%. This strategy highlights the potential for advanced therapeutic combinations to manage relapsed or refractory hematologic cancers effectively.

Explore the latest insights into the complex pathophysiology of steroid-refractory cGVHD and the significant strides made in treatment options, including the impactful roles of ruxolitinib, belumosudil, and ibrutinib in enhancing patient outcomes.

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.